Oncology

Vepdegestrant is an experimental oral PROteolysis TArgeting Chimera that degrades estrogen receptor (ER) in patients with metastatic breast cancer.

Wafa Samara, PharmD, vice president and chief pharmacy officer at City of Hope, highlights the vital role of oncology pharmacists at City of Hope in improving patient outcomes, conducting and leading research, and working as integral members of the multidisciplinary care team.

Even when safe, oral supplement use may not be appropriate to use during cancer treatment or recovery.

Conference Co-Chair and American Association for Cancer Research (AACR) Past President Elaine R. Mardis, PhD, explains that the conference provides pharmacy professionals with insights into the application of large-scale cancer genomics studies to real-world therapeutic responses.

Amir Ali, PharmD, BCOP, discusses his experience as an oncology pharmacist in both direct and indirect patient care at the University of Southern California (USC) Norris Comprehensive Cancer Center.

Pharmacists also navigate the REMS program and monitor and manage adverse effect profiles associated with bispecifics.

The novel formulation of trametinib has the potential to change the treatment paradigm of human papillomavirus (HPV) and prevent infections before they progress to deadly cancers.

The cancers linked with per- and polyfluoroalkyl substance (PFAS) exposure included nonastrocytoma gliomas, acute myeloid leukemia, and Wilms tumors.

A pilot program integrated oncology pharmacists into prior authorization workflows to streamline and expedite medication approvals.

Policymakers and health care providers call for reforms to improve transparency, pricing, and patient access.

Specialty pharmacists are critical for enhanced management of clinical and logistical aspects of treatment.

Adalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.

Camizestrant is an investigational oral selective estrogen receptor degrader.

Dogs share a number of cancers with humans, including melanoma, non-Hodgkin lymphoma, leukemia, and osteosarcoma.

The authors’ findings show a greater decline in those treated with chemotherapy vs endocrine therapy.

The decision is based on clinically meaningful results from a phase 3 trial.

Trastuzumab rezetecan is a novel antibody-drug conjugate.

Patients achieved an overall survival of 12.4 months.

New drugs and collaborative care may be key to overcoming trial closures, weak guidelines, and inefficiencies.

Glecirasib is a potent oral inhibitor of KRASG12C.

Sacituzumab govitecan improves outcomes but requires careful management of adverse effects.

This CAR T-cell therapy has revolutionized the management of high-risk and relapsed or refractory disease.

Fred Saad, MD, discussed findings from the phase 3 ARANOTE and ARASENS trials.

Risk stratification remains a challenge when selecting patients for treatment of smoldering multiple myeloma.

Pembrolizumab is a humanized monoclonal antibody that targets PD-1.

Pharmacists play a crucial role in medication management for these complex patients.

The administration of immunotherapy in adjuvant, neoadjuvant, and perioperative settings offers distinct benefits and challenges in resectable cancers, with recent clinical trials highlighting its potential to improve long-term outcomes and the need for further research into biomarkers and combination strategies.

The drug solidifies its place as a first-line treatment option in AML.